Parexel International Corp. (NASDAQ:PRXL) has been given an average recommendation of “Hold” by the eleven research firms that are presently covering the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $65.43.

A number of analysts have recently weighed in on PRXL shares. Jefferies Group boosted their target price on shares of Parexel International Corp. from $70.00 to $72.50 and gave the stock a “hold” rating in a report on Friday, August 5th. Robert W. Baird downgraded shares of Parexel International Corp. from an “outperform” rating to a “neutral” rating and cut their price target for the company from $78.00 to $67.00 in a report on Thursday, October 27th. Citigroup Inc. upped their price target on shares of Parexel International Corp. from $74.00 to $80.00 and gave the company a “buy” rating in a report on Friday, August 5th. SunTrust Banks Inc. downgraded shares of Parexel International Corp. from a “buy” rating to a “hold” rating and cut their price target for the company from $80.00 to $60.00 in a report on Friday. Finally, Zacks Investment Research upgraded shares of Parexel International Corp. from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th.

Parexel International Corp. (NASDAQ:PRXL) opened at 56.55 on Thursday. The firm’s 50 day moving average is $64.39 and its 200-day moving average is $64.31. Parexel International Corp. has a 52 week low of $51.16 and a 52 week high of $71.13. The company has a market cap of $3.01 billion, a P/E ratio of 17.83 and a beta of 0.91.

Parexel International Corp. (NASDAQ:PRXL) last posted its earnings results on Wednesday, October 26th. The company reported $0.76 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by $0.10. Parexel International Corp. had a return on equity of 30.68% and a net margin of 7.09%. The business earned $500.90 million during the quarter, compared to the consensus estimate of $525.15 million. During the same quarter last year, the firm earned $0.70 earnings per share. The business’s quarterly revenue was down 2.2% on a year-over-year basis. On average, analysts predict that Parexel International Corp. will post $3.76 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in Parexel International Corp. by 1.7% in the first quarter. State Street Corp now owns 1,749,294 shares of the company’s stock valued at $109,733,000 after buying an additional 28,826 shares during the period. Dalton Greiner Hartman Maher & Co. boosted its stake in Parexel International Corp. by 87.6% in the third quarter. Dalton Greiner Hartman Maher & Co. now owns 447,854 shares of the company’s stock valued at $31,103,000 after buying an additional 209,116 shares during the period. Aristotle Capital Boston LLC boosted its stake in Parexel International Corp. by 3.5% in the second quarter. Aristotle Capital Boston LLC now owns 156,770 shares of the company’s stock valued at $9,858,000 after buying an additional 5,298 shares during the period. UBS Asset Management Americas Inc. boosted its stake in Parexel International Corp. by 39.8% in the first quarter. UBS Asset Management Americas Inc. now owns 153,597 shares of the company’s stock valued at $9,635,000 after buying an additional 43,718 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Parexel International Corp. by 4.1% in the first quarter. Metropolitan Life Insurance Co. NY now owns 86,769 shares of the company’s stock valued at $5,443,000 after buying an additional 3,389 shares during the period. 95.54% of the stock is owned by institutional investors.

About Parexel International Corp.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

5 Day Chart for NASDAQ:PRXL

Receive News & Stock Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related stocks with our FREE daily email newsletter.